Trial Profile
An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Sodium benzoate (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors SyneuRx International (Taiwan) corp
- 11 Feb 2024 This trial has been completed in Poland (End Date: 31 Oct 2023), according to European Clinical Trials Database record.
- 10 Sep 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.
- 10 Sep 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Jun 2023.